A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PHOENIX
- Sponsors Janssen Research & Development; Janssen-Cilag
- 11 Dec 2023 Results developing a novel CD5 gene expression signature as a biomarker of response to BTKi-based therapy in diffuse large B-cell lymphoma, pretreatment biopsies from patients enrolled in the PHOENIX study (n = 584), published in the Journal of Clinical Oncology.
- 13 Dec 2021 Results assessing the survival benefit of ibrutinib addition to R-CHOP chemotherapy in younger patients with non-GCB DLBCL, published in the Cancer Cell.
- 26 Nov 2020 This trial has been Discontinued in Italy, according to European Clinical Trials Database.